An economic analysis of physicians' prescribing of selective serotonin reuptake inhibitors

Hospital Pharmacy

Volumn 33, Issue 7, 1998, Pages 847-850

  Viale, Gary L ^a  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

Acquisition costs; Pharmacoeconomics; Prescribing habits; Selective serotonin reuptake inhibitors (SSRIs)

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

COST BENEFIT ANALYSIS; DEPRESSION; DRUG COST; HEALTH CARE COST; HEALTH ECONOMICS; MENTAL HEALTH CARE; PRESCRIPTION; REVIEW;

EID: 0031822205     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8-19.
2. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry. 1993;54:405-418.
3. Jönsson B, Bebbington PE. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry. 1994;164:665-673.
4. Lehtinen V, Joukamaa M. Epidemiology of depression: Prevalence, risk factors and treatment situation. Acta Psychiatr Scand. 1994;77(suppl 3):7-10.
5. Saklad SR. Pharmacoeconomic issues in the treatment of depression. Pharmacotherapy. 1995;15(suppl):76S-83S.
6. Simpson SG, DePaulo JR Jr. Are you recognizing depression in your patients? Postgrad Med. 1993;94:85-93.
7. Wilde MI, Whittington R. Paroxetine: A pharmacoeconomic evaluation of its use in depression. PharmacoEconomics. 1995;8: 62-81.
8. Zung WWK. The role of rating scales in the identification and management of the depressed patient in the primary care setting. J Clin Psychiatry. 1990;51(suppl): 72-76.
9. Wells KB, Sturm R. Care for depression in a changing environment. Health Aff. 1995;14:78-89.
10. Henk HJ, Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW. Medical costs attributed to depression among patients with a history of high medical expenses in a health maintenance organization. Arch Gen Psychiatry. 1996;53:899-904.
11. McFarland BH. Cost-effectiveness considerations for managed care systems: Treating depression in primary care. Am J Med. 1994;97(suppl 6A):47S-58S.
12. Bentkover JD, Feighner JP. Cost analysis of paroxetine versus imipramine in major depression. PharmocoEconomics. 1995;8: 223-232.
13. Burke MJ, Silkey B, Preskorn SH. Pharmacoeconomic considerations when evaluating treatment options for major depressive disorder. J Clin Psychiatry. 1994;55 (suppl A):42-52.
14. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: Economic outcomes in a health maintenance organization. Clin Ther 1994;16:715-730.
15. Simon GE, VonKorff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA. 1996; 275:1897-1902.
16. Skaer TL, Sclar DA, Robison LM, et al. Economic valuation of amitriptyline, desipramine, nortriptyline, and sertraline in the management of patients with depression. Curr Ther Res. 1995;56:556-567.
17. Calabrese DC, Brixner DI, Hildebrand MS. Analysis of selective serotonin reuptake inhibitor utilization in a group model managed care setting. Presented at the Academy for Managed Care Pharmacy, Anaheim, CA, October 1994.
18. Smith W, Sherrill A. A pharmacoeconomic study of the management of major depression: Patients in a TennCare HMO. Med Interface. 1996;July:88-92.
19. Stock AJ, Kofoed L. Therapeutic interchange of fluoxetine and sertraline: Experience in the clinical setting. Am J Hosp Pharm. 1994;51:2279-2281.
20. Navarro R, Valler WE, Spangler M. Antidepressant utilization in managed care: An evaluation of SSRI use in two HMO settings. Med Interface. 1995;August:114-123.
21. Andrews JM, Nemeroff CB. Contemporary management of depression. Am J Med. 1994;97(suppl 6A):24S-32S.
22. Boyer WF, Feighner JP. The financial implications of starting treatment with a selective serotonin reuptake inhibitor or tricyclic antidepressant in drug-naïve depressed patients. In: Jönsson B, Rosenbaum J, eds. Health Economics of Depression. New York, NY: John Wiley & Sons Ltd; 1993, 65-75.
23. Gregor KJ, Overhage JM, Coons SJ, McDonald RC. Selective serotonin reuptake inhibitor dose titration in the naturalistic setting. Clin Ther. 1994;16:306-315.